CA2891394C - Prognostic method for individuals with prostate cancer - Google Patents
Prognostic method for individuals with prostate cancer Download PDFInfo
- Publication number
- CA2891394C CA2891394C CA2891394A CA2891394A CA2891394C CA 2891394 C CA2891394 C CA 2891394C CA 2891394 A CA2891394 A CA 2891394A CA 2891394 A CA2891394 A CA 2891394A CA 2891394 C CA2891394 C CA 2891394C
- Authority
- CA
- Canada
- Prior art keywords
- snppc
- category
- pca
- composite value
- biomarker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Data Mining & Analysis (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Software Systems (AREA)
- Epidemiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Computation (AREA)
- Bioethics (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Databases & Information Systems (AREA)
- Artificial Intelligence (AREA)
- Public Health (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Evolutionary Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1251310 | 2012-11-20 | ||
| SE1251310-7 | 2012-11-20 | ||
| SE1350602-7 | 2013-05-16 | ||
| SE1350602 | 2013-05-16 | ||
| PCT/EP2013/074270 WO2014079874A1 (en) | 2012-11-20 | 2013-11-20 | Prognostic method for individuals with prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2891394A1 CA2891394A1 (en) | 2014-05-30 |
| CA2891394C true CA2891394C (en) | 2023-03-14 |
Family
ID=49713059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2891394A Active CA2891394C (en) | 2012-11-20 | 2013-11-20 | Prognostic method for individuals with prostate cancer |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10428385B2 (enExample) |
| EP (1) | EP2922970B1 (enExample) |
| JP (1) | JP2016508026A (enExample) |
| AU (1) | AU2013349721B2 (enExample) |
| CA (1) | CA2891394C (enExample) |
| ES (1) | ES2694409T3 (enExample) |
| RU (1) | RU2669809C2 (enExample) |
| WO (1) | WO2014079874A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108108590A (zh) | 2012-03-05 | 2018-06-01 | 阿克蒂克合伙公司 | 分析系统和方法 |
| DK2922967T3 (en) | 2012-11-20 | 2018-04-16 | Phadia Ab | PROCEDURE FOR VIEWING A PRESENCE OR NON-PRESENCE OF AGGRESSIVE PROSTATANCES |
| AU2015230017B2 (en) * | 2014-03-11 | 2021-06-17 | A3P Biomedical Ab | Method for detecting a solid tumor cancer |
| MX392384B (es) | 2014-03-28 | 2025-03-24 | Opko Diagnostics Llc | Composiciones y metodos relacionados con el diagnostico de cancer de prostata. |
| US12326453B2 (en) | 2014-03-28 | 2025-06-10 | Opko Diagnostics, Llc | Compositions and methods for active surveillance of prostate cancer |
| EP3253800B1 (en) | 2015-03-27 | 2021-03-03 | Opko Diagnostics, LLC | Prostate antigen standards and uses thereof |
| HK1247824A1 (zh) * | 2015-04-29 | 2018-10-05 | 欧普科诊断有限责任公司 | 用於主动监控前列腺癌的组合物和方法 |
| JP6570929B2 (ja) * | 2015-09-08 | 2019-09-04 | 国立研究開発法人農業・食品産業技術総合研究機構 | 特性推定モデル生成装置および方法、解析対象の特性推定装置および方法 |
| US20190345565A1 (en) * | 2017-02-01 | 2019-11-14 | Phadia Ab | Method for indicating a presence or non-presence of prostate cancer in individuals with particular characteristics |
| WO2019144112A1 (en) * | 2018-01-22 | 2019-07-25 | Phadia Ab | Method for the harmonization of assay results |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| BRPI0807236A2 (pt) | 2007-02-07 | 2019-09-24 | Decode Genetics Ehf | métodos para determinar uma suscetibilidade para câncer de próstata em um indivíduo humano, para identificar um marcador para uso em avaliação de suscetibilidade para câncer de próstata e para genotipificar uma amostra de ácido nucleico obtida de um indivíduo humano sob risco de, ou diagnosticado com, câncer de prostáta, para avaliar um indivíduo humano para probabiliade da resposta a um agente terapêutico para prevenir e/ou melhorar sintomas associados com câncer de próstata, para predizer prognóstico de um indivíduo diagnosticado com câncer e para monitorar progresso de um tratamento de um indivíduo sofrendo tratamento para câncer de próstata, kit para avaliar suscetibilidade para câncer de próstata em um indivíduo humano, uso de uma sonda de oligonucleotídeo, meio legível por computador, e , aparelho para determinar um indicador genético para câncer de próstata em um indivíduo humano. |
| US9732389B2 (en) | 2010-09-03 | 2017-08-15 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with prostate cancer risk |
| US20120202888A1 (en) | 2010-10-08 | 2012-08-09 | The Brigham And Women's Hospital, Inc. | Biomarkers of prostate cancer and predicting mortality |
| US20120150032A1 (en) * | 2010-12-13 | 2012-06-14 | Julius Gudmundsson | Sequence Variants Associated with Prostate Specific Antigen Levels |
| CA2871877A1 (en) | 2012-05-16 | 2013-11-21 | Phadia Ab | Method for indicating the presence or non-presence of prostate cancer |
| DK2922967T3 (en) | 2012-11-20 | 2018-04-16 | Phadia Ab | PROCEDURE FOR VIEWING A PRESENCE OR NON-PRESENCE OF AGGRESSIVE PROSTATANCES |
-
2013
- 2013-11-20 CA CA2891394A patent/CA2891394C/en active Active
- 2013-11-20 ES ES13799501.5T patent/ES2694409T3/es active Active
- 2013-11-20 AU AU2013349721A patent/AU2013349721B2/en active Active
- 2013-11-20 WO PCT/EP2013/074270 patent/WO2014079874A1/en not_active Ceased
- 2013-11-20 EP EP13799501.5A patent/EP2922970B1/en active Active
- 2013-11-20 US US14/443,974 patent/US10428385B2/en active Active
- 2013-11-20 JP JP2015542310A patent/JP2016508026A/ja active Pending
- 2013-11-20 RU RU2015124008A patent/RU2669809C2/ru active
-
2019
- 2019-09-19 US US16/575,940 patent/US20200010912A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2669809C2 (ru) | 2018-10-16 |
| US20150284804A1 (en) | 2015-10-08 |
| WO2014079874A1 (en) | 2014-05-30 |
| JP2016508026A (ja) | 2016-03-17 |
| RU2015124008A (ru) | 2017-01-10 |
| EP2922970A1 (en) | 2015-09-30 |
| US10428385B2 (en) | 2019-10-01 |
| AU2013349721A1 (en) | 2015-05-28 |
| AU2013349721B2 (en) | 2019-03-28 |
| ES2694409T3 (es) | 2018-12-20 |
| EP2922970B1 (en) | 2018-08-08 |
| US20200010912A1 (en) | 2020-01-09 |
| CA2891394A1 (en) | 2014-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3092807C (en) | Method for indicating a presence or non-presence of aggressive prostate cancer | |
| US20200010912A1 (en) | Prognostic method for individuals with prostate cancer | |
| RU2720148C9 (ru) | Способ обнаружения солидной злокачественной опухоли | |
| US20150094221A1 (en) | Method for Indicating the Presence or Non-Presence of Prostate Cancer | |
| JP2022179483A (ja) | 特定の特徴を有する個体において前立腺癌の存在または不存在を示すための方法 | |
| CN105051206B (zh) | 用于指示侵袭性前列腺癌的存在或不存在的方法 | |
| HK1215594B (en) | Method for indicating a presence or non-presence of aggressive prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20181016 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241112 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241112 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20250724 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20250724 Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250724 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250806 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251022 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251022 |